Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiac Involvement Due to COVID-19
Author(s): Valentina O Puntmann , Anastasia Shchendrygina , Carlos Rodriguez Bolanos , et al Added: 1 year ago

Imaging & Diagnostics

COVID-19
Yield and Characterisation of CFT in ANOCA
Author(s): Johanna McChord , Astrid Hubert , Udo Sechtem , et al Added: 7 months ago

Prevention & Chronic Conditions
Separated Vasoreactivity Testing of ACH
Author(s): Shozo Sueda , Tomoki Sakaue Added: 8 months ago

Prevention & Chronic Conditions
ERA 25: eGFR Dips and Disease Severity on Empagliflozin
Author(s): Added: 6 days ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of… View more

Cardiovascular Renal Metabolic
Perfect Vasoreactivity Test
Author(s): Shozo Sueda , Tomoki Sakaue Added: 9 months ago

Prevention & Chronic Conditions

Intervention
Bridging the Gap in Cardio-Renal Care
Author(s): Paola Fioretto , Rajiv Agarwal Added: 6 days ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more

Cardiovascular Renal Metabolic

Guidelines & Statements
ACC.24: Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT
Author(s): David Austin Added: 1 year ago
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity.PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced… View more

CV Disease in Special Populations
Angela Maas
Research Area(s) / Expertise:
Angela Maas has been a cardiologist since 1988, specialising in heart disease in women. She holds a chair in cardiology for womenat Radboud University in Nijmegen, the Netherlands. The main focus of her work is cardiac symptoms in women at middle-age and the role of female-specific risk factors in (early) heart disease. She also founded an expert centre for microvascular coronary disease at the… View more
Coronary Spasm: Ethnic and Sex Differences
Author(s): Peter Ong , Astrid Hubert , Maike Schwidder , et al Added: 2 years ago

Demographic

CV Disease in Special Populations
ESC 23: COP-AF: Colchicine for Perioperative AF
Author(s): David Conen Added: 1 year ago
ESC 2023 — Dr David Conen (McMaster University, CA) joins us onsite for a short interview focussing on the findings from the COP-AF trial (NCT03310125). COP-AF (Population Health Research Institute) aimed to assess if oral colchicine reduced the incidence of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery. 3209… View more

Electrophysiology & Arrhythmia